Since January 2025, CDTI Innovación, through Innvierte, has closed co-investment operations in 48 companies with a commitment of €120.6 million, and has committed investments in 6 investment vehicles with a commitment of €651 million.
CDTI Innovación, promoter and sole shareholder of the company Innvierte, closed 13 co-investment operations in the past months of July and August, 2 of them strategic, amounting to €53,086,000, specifically:
- ABILITY PHARMACEUTICALS, S.A. (Barcelona) is a biopharmaceutical company dedicated to research and development of innovative oral drugs for cancer treatment, based on autophagy as a new therapeutic strategy to induce selective death of cancer cells. The investment is made with Inveready Biotech III SCR, S.A., Inveready Biotech III Parallel SCR, S.A., Pioneers Emporion SCR S.A., CTI Life Sciences Fund III LP and CTI Life Science Fund III (International) LP and CDTI Innovación’s contribution is €720,000.
- ALLOSTERY EXPLORATION TECHNOLOGIES, S.L. (ALLOX) (Barcelona) develops a proprietary technology platform, combining biology and computational technology, to identify allosteric sites in proteins relevant for the treatment of cancer and other diseases through the development of new drugs. The investment is made with Sabadell Asabys Health Innovation Investments II, FCR and Sabadell Asabys Health Innovation Investments 2B, SCR S.A. and CDTI Innovación’s contribution is €1,066,000.
- DENEB MEDICAL, S.L. (Donostia) develops a surgical robotic platform for spinal surgeries. The investment is made with EASO VENTURES II, SCR S.A. and CDTI Innovación’s contribution is €225,000.
- HONEXT MATERIALS, S.L. (HONEXT) (Barcelona) has developed an innovative industrial biotechnological process that transforms primary sludge from the recycled paper industry into circular cellulose boards for interior construction. HONEXT®️ boards, certified as circular, fire-resistant and with a negative carbon footprint, represent a new generation of building materials aligned with circular economy principles and the decarbonization of the sector. The investment is made with P.SAS PONT, S.L. and CDTI Innovación’s contribution is €3,330,000, aimed at accelerating the development and industrialization of this unique technology in Europe.
- INTEGRA THERAPEUTICS S.L. (Barcelona) develops a gene editing platform for the treatment of oncological, autoimmune and genetic-origin diseases. The investment is made with INVIVO VENTURES, FCR, COLUMBUS LIFE SCIENCES FUND III, F.C.R. and AdBio Partners AFB SEED-FUND II and CDTI Innovación’s contribution is €2,700,000.
- MIMARK DIAGNOSTICS, S.L. (Barcelona) develops WomEC, an in vitro diagnostic (IVD) test for Endometrial Cancer (EC), based on the quantification of protein biomarkers present in the soluble fraction of uterine fluid. The investment is made with NARA HEALTH CAPITAL I, F.C.R., INVEREADY BIOTECH IV SCR SA and INVEREADY BIOTECH IV PARALLEL, SCR, S.A. and CDTI Innovación’s contribution is €333,000.
- NÉBODA FARMS, S.L. (Pontevedra) is dedicated to sustainable indoor vertical farming. With a value proposition based on the development of proprietary technology and solid scientific know-how, they currently produce leafy greens and high-value aromatic herbs. The purpose of the round is to optimize the pre-industrial plant and prepare the company for the manufacturing of an industrial plant of 1,800 m2. The investment is made with MONDRAGON FONDO DE PROMOCIÓN II and UNIRISCO GALICIA, S.C.R., S.A. and CDTI Innovación’s contribution is €500,000.
- ONA THERAPEUTICS, S.L. (Barcelona) is a biotech company dedicated to transforming the treatment of advanced and refractory cancer through the development of new innovative therapies using ADCs (Antibody-Drug Conjugates). The investment is made with SABADELL ASABYS HEALTH INNOVATION INVESTMENTS, S.C.R., S.A., ASABYS TOP UP FUND, FCR, YSIOS BIOFUND III, FCRE, ALTA LIFE SCIENCES SPAIN I FCR and FUNDPLUS NV and CDTI Innovación’s contribution is €10,000,000.
- ONCOSTELLAE S.L. (Santiago de Compostela) develops drugs for the treatment of diseases with unmet medical needs in the fields of immunology and women’s health. The investment is made with Bio & Tech Smart Capital, FCRE, Inveready Civilon BI, SCR, SA (formerly called Inveready Innvierte Biotec II, SCR SA) and Unirisco Galicia, SCR, SA., and CDTI Innovación’s contribution is €279,000.
- X1 WIND (Exponential Renewables S.L.) (Barcelona) develops a proven and innovative floating wind system, ready to change the paradigm of the offshore wind industry. The investment is made with CLUB RG 14, S.L. and CDTI Innovación’s contribution is €405,000.
- 011H SUSTAINABLE CONSTRUCTION S.L. (011H) (Barcelona), within the digitalization of the construction sector, has designed a platform aimed at the design and construction of buildings. The investment is made with SEAYA ANDROMEDA SUSTAINABLE TECH FUND I FCR, REDALPINE CAPITAL SCS, SICAR (French investor), BREEGA VENTURE II (Luxembourg investor), BSOCIAL IMPACT FUND, FESE, S.A. and BSOCIAL IMPACT FUND II FESE, S.A.; and CDTI Innovación’s contribution is €5,436,000.
In addition, in the line of strategic companies, CDTI Innovación has committed €17,249,000 to PAYLOAD AEROSPACE, S.L. (Alicante), which develops small satellite launch technologies; and €10,843,000 to XOOPLE, S.L. (Madrid), which provides satellite remote sensing services based on its own GlobalEye constellation.
Since January 2025, CDTI Innovación, through Innvierte, has closed co-investment operations in 48 companies with a commitment of €120.6 million, and has closed investments in 6 investment vehicles with a commitment of €651 million.
Investment vehicles:
In addition, during the past months of July and August, CDTI Innovación, through Innvierte, has committed investments in one investment vehicle for a total of €73,500,000. Specifically:
- KIBO VENTURES FUND IV INNVIERTE, FCRE, managed by KIBO VENTURES PARTNERS, SGEIC, S.A. (Madrid), will invest in software companies with differential technologies and global scalability potential. The fund will focus especially on DeepTech businesses such as cybersecurity, artificial intelligence, robotics, climate, health, education and other disruptive technologies. CDTI Innovación’s commitment amounts to €73,500,000. Kibo Ventures has financed in early stages many of the leading Spanish startups such as Flywire (Nasdaq IPO), Devo, JobandTalent, Vilynx (acquired by Apple) and Onum (acquired by CrowdStrike).
Innvierte
Innvierte is an initiative aimed at promoting business innovation through support for venture capital investment in technology-based or innovative companies. This program is implemented through the closed-end collective investment company Innvierte Economía Sostenible SICC S.M.E., S.A., self-managed and supervised by the Spanish Securities Market Commission (CNMV), of which CDTI Innovación is the sole shareholder.
To date, CDTI Innovación has committed €2.661 billion in 61 investment vehicles that have invested in more than 622 companies, and through its co-investment line it has directly committed €723 million in 190 companies.
Innvierte is part of the Spanish Strategy for Science, Technology and Innovation 2021-2027, approved by the Council of Ministers in September 2020. This Strategy contains the objectives, reforms and measures to be adopted in the entire field of R&D&I in order to boost its growth and impact, and is one of the pillars on which the Government’s R&D&I policy design is based for the coming years.
CDTI Innovación
The Centre for Technological Development and Innovation, CDTI E.P.E., is the innovation agency of the Ministry of Science, Innovation and Universities, whose objective is to promote technological innovation in the business sphere. CDTI’s mission is to ensure that the Spanish business fabric generates and transforms scientific-technical knowledge into globally competitive, sustainable and inclusive growth. In 2024, within the framework of a new strategic plan, CDTI provided more than €2.3 billion in support to Spanish companies and startups.
You can check the conditions of CDTI Innovación’s aid on the website: www.cdti.es
